REOPENING OF THE OFFER FOR A MINIMUM DURATION OF 10 TRADING DAYS
Croissy-Beaubourg, January 16, 2023, 6:00 p.m. CET – THERADIAG (ISIN: FR0004197747, Mnemonic: ALTER), a company specializing in in vitro diagnostics of autoimmune diseases and Theranostics, announces the success of the public tender offer initiated by BIOSYNEX, targeting THERADIAG shares.
The Financial Markets Authority (AMF) published Friday, January 13, 2023 a notice of the final results of the Public Takeover Bid initiated by BIOSYNEX relating to the shares of the company THERADIAG (ISIN code FR0004197747). According to the information communicated by Euronext Paris, 2,826,997 THERADIAG shares were tendered to the centralized offer by Euronext which took place from December 8, 2022 to January 12, 2023 inclusive.
In total, on the basis of a capital composed of 13,118,227 shares representing at most 13,174,282 voting rights, BIOSYNEX will hold on the date of settlement-delivery to take place on January 31, 2023 9,032,820 shares representing as many vote, i.e. 68.86% of the capital and at least 68.56% of the voting rights.
In accordance with the provisions of the AMF General Regulations, the offer will be reopened for a period of at least 10 trading days. The AMF will publish a timetable for the reopening of the offer at a later date. This will allow shareholders who have not yet tendered their shares to do so at the same price, ie €2.30 per THERADIAG share.